BioCentury on BioBusiness,
Monday, January 15, 1996
Scratch below the surface of the cultural gulf between Japanese pharmaceutical companies and biotech companies in the West, and there are two practical problems lurking: biotech companies can't wait as long as it takes for Japanese companies to do a deal, and the Japanese companies are uncomfortable with early stage technology.
Rather than continue to try to fit a square peg into a round hole, Shinichi Tamura of Sosei Co. Ltd. (Tokyo) has set about to recarve the terrain. Sosei, together with an undisclosed Japanese pharmaceutical company, Rothschild's Biotechnology Investments Ltd., Schroder Pacific Technology Partners and Oxford BioScience Partners, set up a $5 million feasibility fund last summer to play the role of both investor, risk-taker and matchmaker.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]